En­cod­ed Ther­a­peu­tics, a well-fund­ed CNS gene ther­a­py mak­er, lays off 10% of staff 

Al­ready two years be­hind ini­tial pro­jec­tions for a Phase I of its lead gene ther­a­py, well-fund­ed En­cod­ed Ther­a­peu­tics is con­serv­ing cash to stay afloat in­to 2026, busi­ness chief David Mc­N­inch con­firmed in an email to End­points News.

The South San Fran­cis­co-based biotech, which last dis­closed a $135 mil­lion Se­ries D in the sum­mer of 2020, has laid off 10% of its work­force, Mc­N­inch said, con­firm­ing a Fierce Biotech re­port. He de­clined to dis­close how many em­ploy­ees were im­pact­ed. The biotech has 195 em­ploy­ees, per da­ta from Pitch­Book.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER